NCT02399592 (Toco-Ovar) is a Phase 2 clinical trial of Bevacizumab in Ovarian Cancer, sponsored by Vejle Hospital.

Who is sponsoring NCT02399592?

NCT02399592 is sponsored by Vejle Hospital.

What drugs are being tested in NCT02399592?

Interventions in NCT02399592: Bevacizumab, Tocotrinol.

What condition does NCT02399592 study?

NCT02399592 studies Ovarian Cancer.

Is NCT02399592 still recruiting?

NCT02399592 is currently completed. Last updated 26 November 2020.

Last reviewed 2020-11-26 · How we verify

NCT02399592: Toco-Ovar

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian Cancer

Completed Phase 2 Last updated 26 November 2020

What this trial tests

Phase 2 trial testing Bevacizumab in Ovarian Cancer in 23 participants. Completed in 1 July 2019.

Timeline

1 March 2015

Primary endpoint
1 July 2019

1 July 2019

Quick facts

Lead sponsor	Vejle Hospital
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	23
Start date	1 March 2015
Primary completion	1 July 2019
Estimated completion	1 July 2019
Sites	1 location across Denmark

Drugs / interventions tested

Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
Tocotrinol — full drug profile →

Conditions studied

Ovarian Cancer — all drugs for Ovarian Cancer →

Sponsor

Vejle Hospital

Who can join

18 and older, female only, with Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Fraction of patients without progression after six months of treatment
Time frame: 6 months after start of treatment

Sponsor's own description

The purpose of this study is to to investigate the effect of tocotrienol as a nutritional supplement in combination with bevacizumab in patients with advanced ovarian cancer.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Natural Forms of Vitamin E as Effective Agents for Cancer Prevention and Therapy.
Jiang Q. · · 2017 · cited 92× · PMID 29141970 · DOI 10.3945/an.117.016329
Tocotrienols Modulate a Life or Death Decision in Cancers.
Tham SY, Loh HS, Mai CW, Fu JY. · · 2019 · cited 22× · PMID 30654580 · DOI 10.3390/ijms20020372
Different Roles of Tocopherols and Tocotrienols in Chemoprevention and Treatment of Prostate Cancer.
Jiang Q. · · 2024 · cited 11× · PMID 38734077 · DOI 10.1016/j.advnut.2024.100240
Utilization of Vitamin E Analogs to Protect Normal Tissues While Enhancing Antitumor Effects.
Aykin-Burns N, Pathak R, Boerma M, Kim T, et al · · 2019 · cited 11× · PMID 30573184 · DOI 10.1016/j.semradonc.2018.10.008

Verify or expand the search:

Other trials of Bevacizumab

Trials testing the same drug.

NCT07504588 — Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and · Phase 2 · not yet recruiting
NCT07500298 — Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable · Phase 1 · not yet recruiting
NCT07271355 — Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colore · Phase 3 · not yet recruiting
NCT07318389 — ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer · EARLY_PHASE1 · not yet recruiting
NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting

Other recruiting trials for Ovarian Cancer

Currently open trials in the same condition.

NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Vejle Hospital trials

Trials by the same sponsor.

NCT05776381 — The Impact of a Patient Decision Aid on Treatment Choices for Patients With an Unexpected Malignant Colorectal Polyp · Phase 2 · not yet recruiting
NCT07281820 — FRAME - Implementation of a PRO Measure to Inform Patient-Centered Survivorship Care in Oncology Outpatient Visits · NA · recruiting
NCT07511881 — Far-UVC and Infections in Long-term Care Facilities · NA · completed
NCT06279143 — The Diagnostic Accuracy of Advanced Imaging in Identifying Suspected Skin Cancer (Basal Cell Carcinoma) Around the Eyes · recruiting
NCT06240078 — Impact of COPD on Sexual Health, Loneliness, and Well-being · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02399592 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vejle Hospital
Last refreshed: 26 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02399592.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing